Connor Clark & Lunn Investment Management Ltd. Has $3.24 Million Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) by 244.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 589,471 shares of the company's stock after purchasing an additional 418,139 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned 0.38% of Xeris Biopharma worth $3,236,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in XERS. JPMorgan Chase & Co. raised its position in Xeris Biopharma by 166.2% during the fourth quarter. JPMorgan Chase & Co. now owns 1,043,441 shares of the company's stock worth $3,537,000 after acquiring an additional 651,481 shares in the last quarter. Geode Capital Management LLC raised its position in Xeris Biopharma by 0.5% during the fourth quarter. Geode Capital Management LLC now owns 3,351,426 shares of the company's stock worth $11,364,000 after acquiring an additional 17,956 shares in the last quarter. Wells Fargo & Company MN raised its position in Xeris Biopharma by 38.7% during the fourth quarter. Wells Fargo & Company MN now owns 79,036 shares of the company's stock worth $268,000 after acquiring an additional 22,050 shares in the last quarter. Russell Investments Group Ltd. raised its position in Xeris Biopharma by 1,496.3% during the fourth quarter. Russell Investments Group Ltd. now owns 17,974 shares of the company's stock worth $61,000 after acquiring an additional 16,848 shares in the last quarter. Finally, Legal & General Group Plc raised its position in Xeris Biopharma by 9.3% during the fourth quarter. Legal & General Group Plc now owns 230,467 shares of the company's stock worth $781,000 after acquiring an additional 19,624 shares in the last quarter. Institutional investors own 42.75% of the company's stock.

Insiders Place Their Bets

In other Xeris Biopharma news, Director John Johnson sold 107,500 shares of the stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $7.32, for a total transaction of $786,900.00. Following the sale, the director directly owned 833,483 shares in the company, valued at $6,101,095.56. This represents a 11.42% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Dawn Halkuff sold 42,500 shares of the stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $7.28, for a total transaction of $309,400.00. Following the sale, the director owned 115,000 shares in the company, valued at $837,200. The trade was a 26.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 6.47% of the company's stock.

Xeris Biopharma Stock Performance

NASDAQ:XERS traded up $0.38 during mid-day trading on Friday, reaching $7.68. 3,517,509 shares of the company's stock were exchanged, compared to its average volume of 3,070,274. Xeris Biopharma Holdings, Inc. has a one year low of $2.48 and a one year high of $7.72. The firm has a market capitalization of $1.24 billion, a PE ratio of -36.57 and a beta of 0.65. The business's fifty day simple moving average is $5.23 and its two-hundred day simple moving average is $4.71.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.02. The business had revenue of $67.71 million for the quarter, compared to the consensus estimate of $64.58 million. As a group, equities research analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on XERS. Wall Street Zen raised shares of Xeris Biopharma from a "hold" rating to a "strong-buy" rating in a research report on Saturday, August 9th. Oppenheimer increased their price objective on shares of Xeris Biopharma from $6.00 to $7.00 and gave the company an "outperform" rating in a research report on Friday, May 9th. Finally, HC Wainwright raised shares of Xeris Biopharma to a "buy" rating and set a $10.00 price objective on the stock in a research report on Tuesday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $6.58.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.